EpiPen

Martin Shkreli, former CEO of Turing Pharmaceuticals, appeared before the House Oversight Committee during a contentious hearing on drug pricing on Feb. 4, 2016.

Health & Safety

A Decade Marked By Outrage Over Drug Prices

3:08pm December 31, 2019

by Sydney Lupkin

Nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Over the past decade, high prices of several medicines have become flashpoints.

A new generic that pharmacists can automatically substitute for Mylan's EpiPen will soon be on the market.

Health & Safety

FDA Approves New Generic Version Of The EpiPen For Allergic Reactions

4:58pm August 16, 2018

by Rob Stein

Consumers will have a new generic alternative to the widely used — and pricey — device to counter life-threatening allergic reactions.

An EpiPen Jr. epinephrine auto-injector. Some EpiPens have been recalled from the U.S. market over concerns that they could fail to activate when people try to use them.

Recall Of Some EpiPens Extends To U.S.

4:02pm April 03, 2017

by Jessica Boddy

Mylan is recalling some EpiPens distributed between December 2015 and July 2016, saying a potentially defective part could make them fail to activate during a life-threatening allergic reaction.

Mylan CEO Heather Bresch defended pricing for the company's EpiPen on Capitol Hill in September.

Mylan To Sell Generic EpiPen At Half The Price Of Original

5:36pm December 16, 2016

by Alison Kodjak

Drugmaker Mylan is launching a generic version of its own EpiPen. The lower price could quiet criticism about the high cost of the brand-name anti-allergy drug. There's also a business twist.

An Alternative To The EpiPen Is Coming Back To Drugstores

10:47am October 26, 2016

by Alison Kodjak

The Auvi-Q epinephrine injector was pulled from the market in 2015 because of quality concerns. Now, the drug's maker says the problems have been solved and Auvi-Q will be available again in 2017.

Rethinking Automatic Insurance Coverage For Preventive Health Care

5:32pm October 10, 2016

by Alison Kodjak

Three former leaders of an influential task force that issues guidelines for preventive care says insurance coverage for highly rated tests and services shouldn't be mandatory.

Queue Listen Now

Mylan CEO Claims EpiPens Aren't As Profitable As Everyone Thinks

4:30pm September 21, 2016

by Alison Kodjak

In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.

Heather Bresch, CEO of Mylan, says that EpiPens "need to be everywhere."

EpiPen's Dominance Driven By Competitors' Stumbles And Tragic Deaths

2:09pm September 07, 2016

by Pauline Bartolone

The company's lobbying of state legislatures is just one factor in EpiPen's dominance of the market. Manufacturers of competing devices have struggled to gain a foothold.

Where are the generic alternatives to EpiPen and other expensive drugs that have lost patent protection?

FDA Fees On Industry Haven't Fixed Delays In Generic Drug Approvals

4:34pm September 01, 2016

by Sydney Lupkin

Four years after user fees were imposed to speed up the review of generic drug applications by the Food and Drug Administration, more than 4,000 generics remain in limbo.

Mylan, the maker of EpiPen, says it will sell a generic version for $300 for a two-pack, a price that consumer advocates say is still too high. The device is used to treat severe allergic reactions.

Health & Safety

Maker Of EpiPen To Sell Generic Version For Half The Price

5:21pm August 29, 2016

by Alison Kodjak

Mylan's move comes amid pressure from consumers and Congress to lower the allergy drug's price. In less than 10 years, the price has risen from about $100 to more than $600 for an injector two-pack.

Queue Listen Now